Salbutamol inhaler and nebuliser — Indian WHO-GMP supply for NHS asthma, GCC respiratory tenders and African public-sector procurement.
The reference short-acting beta-2 agonist for acute asthma, acute COPD exacerbation and exercise-induced bronchospasm. 100mcg pressurised metered-dose inhalers and 2.5mg / 5mg unit-dose nebuliser ampoules from Indian WHO-GMP facilities. The most-tendered respiratory molecule globally. NICE NG80 acute asthma pathway-aligned, NICE NG115 COPD exacerbation-aligned, GINA 2023 SABA-reliever and AIR-paradigm-aware documentation pack. WHO EML core item, multiple Indian partner lines under WHO Prequalification for Global Fund and donor procurement.
Multiple WHO-GMP partner lines · 100mcg pMDI canisters · 2.5mg and 5mg unit-dose nebuliser ampoules · CTD dossier on file · WHO EML core list · The most-tendered respiratory molecule globally.
Active ingredient
Salbutamol sulfate. Selective short-acting beta-2 adrenoceptor agonist (SABA). Mechanism: binds beta-2 receptors on bronchial smooth muscle to activate adenylyl cyclase, raise intracellular cAMP, relax smooth muscle and produce bronchodilation within 1-5 minutes of inhalation. Onset 1-5 min by inhalation, peak effect 30-90 min, duration 3-6 hours. Beta-1 cardiac selectivity is approximately 1:1000 at therapeutic inhaled doses but is lost at supratherapeutic doses (tachycardia, palpitations, tremor).
Strengths and forms stocked
100mcg per actuation pressurised metered-dose inhaler (pMDI), 200 actuations per canister — the high-volume reliever inhaler line, supplied in standard pMDI canisters with HFA propellant (HFA-134a or HFA-227) per current EMA / MHRA / SFDA labelling. 2.5mg/2.5ml unit-dose nebuliser ampoule — paediatric and mild-adult acute exacerbation. 5mg/2.5ml unit-dose nebuliser ampoule — standard adult acute severe asthma and acute COPD exacerbation. Oral 2mg / 4mg tablets and 2mg/5ml syrup — declining use globally but still tendered in some LMIC paediatric formularies. Hospital-pack 20-ampoule and 40-ampoule cartons for acute trust respiratory wards on request.
Indications scope
Acute relief of bronchospasm in asthma (NICE NG80, BTS/SIGN 158, GINA 2023), acute severe asthma (nebulised, oxygen-driven), acute COPD exacerbation (NICE NG115, GOLD 2024), exercise-induced bronchoconstriction. Important paradigm note: GINA 2023 / NICE NG80 (2024 update) no longer recommend SABA monotherapy for asthma in adults and adolescents; the AIR (anti-inflammatory reliever) approach with ICS-formoterol is preferred. Salbutamol remains the universal acute reliever in COPD, paediatric asthma (limited evidence base for AIR in children under 6), low-resource settings where ICS-formoterol cost is prohibitive, and emergency-department / hospital acute care.
Buyer fit
UK NHS community pharmacy at Drug Tariff Category M generic dispensing scale — the highest-volume respiratory reliever line. UK NHS hospital pharmacy nebuliser ampoules for acute respiratory wards and A&E. GCC asthma and COPD tender desks: SFDA (KSA, NUPCO framework), MoHAP (UAE), CMSPS (Kuwait), MoPH (Qatar), MoH/OFDA (Oman), NHRA (Bahrain). African public-sector procurement: NAFDAC (Nigeria), KEMSA (Kenya), CMS (Ghana), SAHPRA (South Africa), EFDA (Ethiopia). Global Fund and donor procurement: WHO EML core list status opens Global Fund respiratory comorbidity tenders, UNICEF child-health respiratory programmes, MSF emergency respiratory packs.
What we file with the quote
Indian manufacturer's CDSCO Form 26 export licence, EU-GMP / WHO-GMP certificate, Certificate of Pharmaceutical Product (CoPP) per WHO format for the destination regulator, batch Certificate of Analysis (CoA) with assay, content uniformity (critical for pMDI), particle-size distribution data (for inhaled aerosol), microbial limits (nebuliser solution), and the manufacturer's BP/USP/EP-aligned monograph compliance. HFA propellant compliance documentation, SmPC and PIL per destination regulator's format with paradoxical-bronchospasm and hypokalaemia warnings verbatim, full CTD Module 1-5 dossier for new-market registration, and NHS Drug Tariff line confirmation for UK community-pharmacy buyers.
Lead times
pMDI canisters ship in 14-21 working days from PO ex-Mumbai for stock lines; pMDI manufacturing has longer cycle time than oral solid dosage due to propellant fill, leak testing and pre-shipment functional testing. Unit-dose nebuliser ampoules ship in 10-14 working days for stock lines. Tender quantities (>100K canisters or >500K ampoules) require campaign batch scheduling; lead time 5-8 weeks from PO. Ambient transport for both forms but pMDI canisters require below 30°C and protection from direct heat and puncture during transit; nebuliser solution requires light-protective packaging.
Four buyer-channel models for an Indian-manufactured salbutamol export.
Salbutamol is the highest-volume respiratory tender molecule globally. NHS community pharmacy, hospital nebuliser supply, GCC respiratory tender desks and African public-sector asthma / COPD procurement are the four dominant channels — each with different paperwork tracks and dose-form mixes.
UK NHS community pharmacy and hospital
NHS Drug Tariff Category M generic dispensing for the 100mcg pMDI canister — the highest-volume community-pharmacy respiratory reliever line in England, Wales and Northern Ireland. Hospital pharmacy nebuliser ampoules (2.5mg/2.5ml and 5mg/2.5ml) for acute respiratory wards, A&E and ITU acute severe asthma protocols. M Care supplies UK WDA(H)-licensed wholesalers against NHS framework agreements, with QP audit pack on file for EU/UK GMP equivalence, batch-by-batch Certificate of Analysis (CoA) including pMDI content uniformity and particle-size distribution data, and Article 40 / EU-IMPD release pathway through partner UK MIA(IMP) holders for non-EEA imports post-Brexit. Pricing follows Cat M reimbursement bands; the inhaler line is environmentally scrutinised under NHS Long Term Plan low-carbon prescribing — DPI (dry powder inhaler) alternatives are formulary-preferred in many ICBs but pMDI salbutamol remains the universal acute reliever.
GCC respiratory tender supply
Gulf Health Council Central Registration route or state-by-state via SFDA (KSA, NUPCO framework), MoHAP (UAE), CMSPS (Kuwait), MoPH (Qatar), MoH/OFDA (Oman), NHRA (Bahrain). Salbutamol is on every GCC state's essential medicines list and on the Saudi NCD initiative Mandatory Reserve List for asthma management. Saudi NUPCO framework responses for hospital tenders with three-manufacturer redundancy across pMDI and nebuliser forms. Arabic SmPC + PIL translations on file with paradoxical-bronchospasm and hypokalaemia warnings verbatim. GCC desert-climate ambient storage is well within pMDI canister tolerance (below 30°C), but transit through high-temperature lanes requires pre-validated logistics planning.
African public-sector respiratory procurement
NAFDAC (Nigeria), PPB (Kenya), FDA (Ghana), SAHPRA (South Africa), EFDA (Ethiopia), TMDA (Tanzania) registration pathways. WHO Prequalification active for several Indian salbutamol generic lines (both pMDI and nebuliser solution), opening Global Fund respiratory comorbidity programmes, UNICEF child-health respiratory tenders, WHO emergency respiratory packs for outbreak response, and MSF field-hospital respiratory supplies. Sea-freight LCL/FCL via Mumbai / Nhava Sheva to Lagos / Mombasa / Durban / Dar es Salaam is the standard logistics lane; 6-8 week sea transit with light-protective packaging for nebuliser solution. Hospital-pack 20-ampoule and 40-ampoule cartons for teaching-hospital respiratory wards on request.
EU and other regulated markets
EU member states via Article 40 importation licence held by partner MIA(IMP) and QP batch certification; LATAM via ANVISA (Brazil), COFEPRIS (Mexico), INVIMA (Colombia), DIGEMID (Peru); SEA via Philippines FDA, Vietnam DAV, Indonesia BPOM, Malaysia NPRA, Bangladesh DGDA. Salbutamol is registered in 100+ countries via Indian generic manufacturers; M Care's role is dossier and tender-pack assembly, not standalone manufacturing. HFA propellant compliance documentation is required for EU pMDI registrations under the EU F-Gas Regulation transition framework — M Care partner manufacturers operate on HFA-134a / HFA-227 propellants per current EMA / MHRA labelling.
AIR paradigm shift, hypokalaemia risk, paradoxical bronchospasm, environmental footprint — salbutamol is universal but the prescribing landscape is moving.
Adult acute relief dose is 100-200mcg (1-2 puffs) pMDI as needed, with a spacer if technique is suboptimal. Acute severe asthma: 2.5-5mg nebulised every 20-30 minutes initially, then every 1-4 hours, oxygen-driven (21% oxygen if SpO2 risk, otherwise per BTS/SIGN 158). Acute COPD exacerbation: 2.5-5mg nebulised every 4-6 hours, oxygen-driven with caution to avoid hyperoxia per NICE NG115. Paediatric dose: 100mcg pMDI 1-2 puffs as needed, or nebulised 2.5mg under 5 years / 5mg over 5 years. The single most important prescribing nuance is the GINA 2023 paradigm shift: SABA monotherapy is no longer recommended for asthma in adults and adolescents over 12 years. The AIR (anti-inflammatory reliever) approach using ICS-formoterol combinations is preferred for both reliever and maintenance therapy. Excess SABA use (>3 canisters per year) is associated with increased exacerbation and mortality risk; pharmacy reliever-canister dispensing is a key audit metric in NHS GP and ICB asthma quality frameworks. Salbutamol remains universal in: COPD (no AIR-equivalent paradigm), paediatric asthma under 6 (limited AIR evidence), emergency-department acute severe asthma (universal nebuliser line), and low-resource settings where ICS-formoterol cost is prohibitive. Tremor and palpitations are dose-related — universal but rarely treatment-limiting at standard inhaled doses; supratherapeutic doses cause tachycardia and ventricular ectopy. Hypokalaemia is a recognised signal at high doses, particularly when combined with theophylline, corticosteroids, loop diuretics or thiazides — measure potassium in any patient on continuous nebulisation or chronic high-dose SABA. Paradoxical bronchospasm is rare but recognised; if the inhaler appears to worsen symptoms acutely, withdraw and reassess for HFA-propellant or excipient hypersensitivity. Lactic acidosis is documented with high-dose continuous nebulised salbutamol in acute severe asthma — measure lactate and arterial blood gas in any nebulised patient who is not improving. Environmental footprint: HFA-propellant pMDI canisters have a high greenhouse-gas footprint; NHS Long Term Plan low-carbon prescribing favours DPI (dry powder inhaler) alternatives where clinically appropriate. Cross-class allergy: salbutamol allergy is rare; cross-reactivity with terbutaline, formoterol or salmeterol uncommon but cautious if anaphylactic. Pregnancy: salbutamol is widely used in pregnancy for asthma maintenance; the risk-benefit favours uncontrolled asthma exposure > controlled asthma on therapy. M Care does not provide clinical advice — the destination-country regulator's SmPC, NICE NG80 / NG115, GINA 2023, BTS/SIGN 158 and the local respiratory formulary are the prescribing references.
Five regulatory tracks for an Indian-manufactured salbutamol export.
Salbutamol is registered in 100+ countries via Indian generic manufacturers. The dossier work for any new market is typically CTD Module 1 country-specific assembly plus Module 3 reuse, but the pMDI form has form-specific regulatory hotspots: HFA propellant compliance, particle-size distribution testing, and content uniformity validation that are not present for oral solid dosage.
WHO Essential Medicines List
Salbutamol is on the WHO Model List of Essential Medicines (23rd edition, 2023) as the core-list short-acting beta-2 agonist for asthma and acute bronchospasm. WHO EML status is the gateway to WHO Prequalification assessment and Global Fund respiratory-comorbidity tender eligibility. Multiple Indian salbutamol generic manufacturers hold active WHO PQ status across both pMDI and nebuliser solution lines. The WHO Package of Essential Noncommunicable Disease Interventions (PEN) identifies salbutamol as essential primary-care infrastructure.
MHRA (United Kingdom)
Salbutamol is registered with the MHRA across multiple PL holders covering 100mcg pMDI canisters, 2.5mg/2.5ml and 5mg/2.5ml unit-dose nebuliser ampoules, and oral 2mg / 4mg tablet / syrup forms. NHS Drug Tariff Category M generic dispensing applies. NICE NG80 (asthma diagnosis and monitoring, 2017 with 2024 update on AIR-paradigm shift), NICE NG115 (COPD acute exacerbation, 2018), BTS/SIGN 158 (acute severe asthma) are the reference guidelines. MHRA Drug Safety Update on excess SABA prescribing as an asthma exacerbation risk marker is the active surveillance issue; pMDI canisters now carry the paradoxical-bronchospasm warning verbatim.
EMA (European Union) and EU member states
Decentralised Procedure or Mutual Recognition Procedure registrations across EU/EEA via national medicines agencies. Article 40 importation licence via partner MIA(IMP) holder for non-EEA-manufactured supply with EU-zone QP batch certification. HFA propellant compliance under the EU F-Gas Regulation transition framework — HFA-134a and HFA-227 propellants are currently approved but under environmental review; M Care partner manufacturers operate on the current EMA-approved propellants and monitor the F-Gas transition. The EMA SmPC harmonised guidance carries the GINA 2023 AIR-paradigm-aware AS-IF-NEEDED-only positioning for adults.
GCC and Middle East
Gulf Health Council Central Registration route covering KSA, UAE, Kuwait, Qatar, Oman, Bahrain. State-by-state where Central Registration not in scope: SFDA (KSA), MoHAP/DHA (UAE), CMSPS (Kuwait), MoPH (Qatar), MoH/OFDA (Oman), NHRA (Bahrain). Salbutamol is on every state's essential medicines list. Saudi NCD initiative places salbutamol on the Mandatory Reserve List for asthma management. NUPCO framework responses for large hospital tenders with three-manufacturer redundancy. Arabic SmPC carries the GINA 2023 AIR-paradigm-aware reliever positioning and the paradoxical-bronchospasm and hypokalaemia warnings translated from the SFDA reference.
African and LMIC markets
NAFDAC (Nigeria), PPB (Kenya), FDA Ghana, SAHPRA (South Africa), EFDA (Ethiopia), TMDA (Tanzania), NDA (Uganda) registration pathways. WHO Prequalification opens donor-funded pooled procurement at concessional pricing for Global Fund respiratory comorbidity, UNICEF child-health respiratory programmes, WHO emergency respiratory packs and MSF field-hospital respiratory supplies. African public-sector formulary committees typically follow WHO PEN guidance for primary-care asthma; salbutamol pMDI remains universal where ICS-formoterol AIR cost is prohibitive. Pharmacy stock-out is the dominant respiratory care gap in sub-Saharan Africa and reliable supply continuity is the procurement priority.
Salbutamol's tender-line and clinical companion molecules.
Asthma and COPD tenders rarely come single-line. Salbutamol pairs with inhaled corticosteroids (ICS) and ICS-LABA combinations in the maintenance backbone, and with ipratropium in acute exacerbations. Internal links to the molecules and services already covered, with the wider respiratory category roadmap.
Respiratory category overview
Asthma and COPD bronchodilators (SABA, LABA, LAMA, ICS, ICS-LABA, ICS-LABA-LAMA triple), antihistamines, leukotriene antagonists, mucolytics. Respiratory tender lines are rarely single-molecule.
GCC tender response service
SFDA, NUPCO and state-by-state tender desks for salbutamol alongside the broader respiratory pack. Three-manufacturer-redundancy quotes.
NHS tender response service
Acute trust hospital nebuliser ampoule supply for A&E and ITU, plus Cat M community pharmacy chain supply.
WHO-GMP compliance service
WHO-PQ pathway support for the Indian partner manufacturer's salbutamol lines into Global Fund and donor procurement.
NGO and donor procurement
Global Fund respiratory comorbidity, UNICEF child-health respiratory programmes, MSF emergency packs. WHO-PQ documentation pack on file.
African public-sector procurement
NAFDAC, KEMSA, SAHPRA, EFDA pathways for the Africa-tender salbutamol lines. Light-protective packaging and 6-8 week sea-freight transit.
How a salbutamol enquiry becomes a sustained supply contract.
- Send us the specifics. WhatsApp the Mumbai line or send the contact form. We need destination country, dose-forms required (pMDI canister, 2.5mg or 5mg nebuliser ampoule, oral tablet or syrup), per-month or per-tender volume, buyer profile (NHS framework, GCC tender desk, African MoH, NGO, EU community-pharmacy chain), and pack format (single canister vs hospital-pack 20/40-ampoule cartons). Reply within one working day with a provisional quote and the Indian partner manufacturer best-fit per form.
- Three-manufacturer-redundancy quote. M Care quotes three Indian partner manufacturers per dose-form for tender-supply redundancy — different manufacturers may be best-fit for pMDI vs nebuliser solution depending on the partner's installed manufacturing equipment. Pricing FOB Mumbai or CIF destination port, packaged per buyer specification. Quote includes per-canister or per-ampoule ex-works pricing, freight, dossier preparation fee (if new registration), and destination-country regulatory fees (passed through at cost). Quote validity 30 days from issue.
- Dossier preparation. For existing registrations, M Care provides batch-specific CoA (with pMDI content uniformity, particle-size distribution, leak rate; or nebuliser microbial limits and bacterial endotoxin), CoPP per WHO format, HFA propellant compliance certificate (for pMDI), and SmPC/PIL country overlay within 5-10 working days from PO. For new-market registration, we assemble the full CTD Module 1-5 dossier — Module 3 quality data is partner-manufacturer-specific and reused; Module 1 administrative is country-specific. Inhaled dosage forms have more demanding stability and performance testing than oral solids — typical full-dossier preparation 45-60 working days; new-market regulatory review 6-18 months.
- Manufacturing campaign and freight. pMDI canisters from stock lines ship in 14-21 working days from PO; pMDI manufacturing has longer cycle time than oral solid dosage due to propellant fill, leak testing and pre-shipment functional testing. Nebuliser ampoules ship in 10-14 working days for stock lines. Tender quantities >100K canisters or >500K ampoules require dedicated campaign batches with 5-8 week PO-to-shipment timeline. pMDI canister transport: ambient with below-30°C ceiling and protection from direct heat and puncture; air freight or sea freight both supported with appropriate route validation. Nebuliser solution transport: ambient with light-protective packaging; sea freight LCL/FCL via Nhava Sheva for tender volumes.
- Ongoing supply and pharmacovigilance. Post-shipment: M Care provides monthly Drug Tariff line confirmation for UK NHS buyers, SFDA / NUPCO monthly availability confirmations for GCC tender desks, and CSV / Excel tender-line trackers for African public-sector buyers. Pharmacovigilance reporting (UK Yellow Card / EU EudraVigilance / SFDA NPC / NAFDAC PV unit) is the partner manufacturer's MAH responsibility; M Care coordinates local responsible person paperwork. Major ADR signals: paradoxical bronchospasm, severe hypokalaemia, lactic acidosis on continuous nebulisation. Excess SABA dispensing audit data shared with NHS ICB and equivalent commissioning organisations on request — this is an active asthma-quality marker.
Salbutamol inhaler and nebuliser supply — buyer FAQ.
What dose-forms of salbutamol do M Care supply?
100mcg per actuation pressurised metered-dose inhaler (pMDI), 200-actuation canister — the high-volume reliever inhaler line. 2.5mg/2.5ml and 5mg/2.5ml unit-dose nebuliser ampoules — the acute exacerbation hospital pharmacy lines. Oral 2mg and 4mg tablets and 2mg/5ml syrup — legacy and declining use globally but still tendered in some LMIC paediatric formularies. Single-canister and hospital-pack 20-ampoule / 40-ampoule cartons available per buyer specification. HFA-134a or HFA-227 propellant for pMDI per current EMA / MHRA / SFDA labelling.
Can M Care supply ICS-formoterol AIR combinations alongside salbutamol?
Yes — ICS-formoterol combinations (budesonide-formoterol, beclometasone-formoterol) are available from M Care's partner manufacturer network. The GINA 2023 paradigm shift to anti-inflammatory reliever (AIR) therapy with ICS-formoterol means many tenders now bundle salbutamol with an ICS-formoterol line for the AIR-preferred maintenance plus a SABA reserve for paediatric, COPD and acute-care indications. ICS-formoterol combinations are quoted on a separate workflow because they require a separate Module 1 regulatory dossier per destination and follow different campaign cadences.
How does the HFA-propellant environmental footprint affect tender competitiveness?
HFA-propellant pMDI canisters have a significantly higher greenhouse-gas footprint than DPI (dry powder inhaler) alternatives. The NHS Long Term Plan low-carbon prescribing initiative favours DPI alternatives where clinically appropriate, and many ICBs and acute trusts now have low-carbon inhaler formulary preferences. Salbutamol DPI is technically feasible but the global generic market still dominantly offers pMDI; M Care can quote DPI partner manufacturer lines where the destination tender specifies low-carbon prescribing as a scoring criterion. The EU F-Gas Regulation transition framework is the live environmental regulatory issue — current HFA-134a and HFA-227 propellants are approved but under environmental review.
Is salbutamol a controlled drug or schedule-restricted in any market?
No — salbutamol is a standard prescription-only medicine (POM) in most markets and available as a community pharmacy over-the-counter inhaler in several (UK behind-the-counter, some EU). It is not controlled, scheduled or otherwise restricted under the UN Single Convention or UN Convention on Psychotropic Substances. Sport prescribing note: salbutamol is on the WADA permitted list with a daily-dose ceiling (1600mcg over 24 hours, 800mcg over 12 hours) and a 1000 ng/mL urinary threshold; competitive athletes need standard inhaled-asthma management with documented Therapeutic Use Exemption (TUE) where the threshold may be exceeded.
What documentation is included with a salbutamol consignment?
Every consignment ships with batch-specific Certificate of Analysis (pMDI: assay, content uniformity, particle-size distribution, leak rate; nebuliser solution: assay, microbial limits, bacterial endotoxin per USP <85>; oral tablets: assay, dissolution, related substances), Method of Analysis, Certificate of Pharmaceutical Product (CoPP), WHO-GMP certificate, manufacturing licence, WHO-PQ confirmation where applicable, HFA propellant compliance certificate (for pMDI), Certificate of Origin, destination-language PIL with paradoxical-bronchospasm and hypokalaemia warnings, and the GINA 2023 AIR-paradigm-aware reliever positioning. Full list under respiratory.
What's the typical lead time for tender quantities?
pMDI canisters from stock lines ship in 14-21 working days from PO. Nebuliser ampoules from stock 10-14 working days. Tender quantities (>100K canisters or >500K ampoules) require dedicated campaign batches with 5-8 week PO-to-shipment. pMDI has longer cycle time than oral solid dosage due to propellant fill, leak testing and pre-shipment functional testing. Air freight to UK / GCC: 3-5 days; sea freight to Africa: 6-8 weeks via Mumbai / Nhava Sheva to Lagos / Mombasa / Durban / Dar es Salaam, with ambient transport, below-30°C ceiling for pMDI and light-protective packaging for nebuliser solution.
How should procurement structure salbutamol orders given the GINA 2023 AIR-paradigm shift?
The GINA 2023 / NICE NG80 (2024 update) paradigm shift to ICS-formoterol AIR (anti-inflammatory reliever) for adult and adolescent asthma reduces the salbutamol reliever-canister demand projection for adult asthma but does not affect the demand for COPD acute relief, paediatric asthma under 6, emergency-department nebulised acute severe asthma, or LMIC primary-care settings where ICS-formoterol cost is prohibitive. Procurement should split the salbutamol tender into community-pharmacy reliever (declining adult asthma share, stable COPD share, stable paediatric share) and hospital-pharmacy nebuliser (acute care, no AIR equivalent). Excess SABA dispensing audit data (>3 canisters per patient per year as an asthma exacerbation risk marker) is the active NHS pharmacy quality framework; expect community-pharmacy salbutamol pMDI demand to decline gradually as AIR uptake increases.
Salbutamol inhaler and nebuliser — three-manufacturer-redundancy supply for NHS asthma, GCC respiratory tenders and African public-sector procurement.
Salbutamol is the most-tendered respiratory molecule globally and the universal acute reliever, but the prescribing landscape is moving — GINA 2023 AIR paradigm for adult asthma, NHS Long Term Plan low-carbon prescribing, EU F-Gas Regulation propellant transition. M Care holds three Indian partner manufacturers per dose-form for supply redundancy, with NHS Cat M, SFDA, NUPCO, NAFDAC, KEMSA, SAHPRA and EU MIA(IMP) registrations all on file or readily assembled.